A $100 Million Biotech Deal Is Also A Tale Of Two Executives Facing Their Kids Deadly Diseases

Sep 21, 2018, 14:42 PM by Michael Croft

Forbes | Amicus Therapertics is purchasing a portfolio of ten gene therapies for $100 million. But there's more to this story than most business deals.

September 21, 2018 | Amicus Therapertics is purchasing a portfolio of ten gene therapies for $100 million. But there's more to this story than most business deals. Forbes